BeiGene
BGNE
#881
Rank
A$33.26 B
Marketcap
$302.96
Share price
1.71%
Change (1 day)
0.85%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

EPS for BeiGene (BGNE)

EPS in 2023 (TTM): -$25.10

According to BeiGene 's latest financial reports the company's current EPS (TTM) is -$24.96. In 2022 the company made an earnings per share (EPS) of -$29.05 a decrease over its 2021 EPS that were of -$22.81.

EPS history for BeiGene from 2015 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$25.10-13.61%
2022-$29.0527.35%
2021-$22.81-19.96%
2020-$28.5020.81%
2019-$23.5931.52%
2018-$17.94417.57%
2017-$3.47-37.16%
2016-$5.52158.95%
2015-$2.13

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$1.50-93.99%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.40-98.38%๐Ÿ‡บ๐Ÿ‡ธ USA